SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1532 0979
 

Sökning: L773:1532 0979 > Tumor Microenvironm...

Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma - New Therapeutic Targets

Mitteldorf, C. (författare)
Berisha, A. (författare)
Pfaltz, Monique C. (författare)
visa fler...
Broekaert, S. M. C. (författare)
Schän, M. P. (författare)
Kerl, K. (författare)
Kempf, W. (författare)
visa färre...
Lippincott Williams and Wilkins, 2017
2017
Engelska.
Ingår i: American Journal of Surgical Pathology. - : Lippincott Williams and Wilkins. - 0147-5185 .- 1532-0979. ; 41:7, s. 998-1004
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Programmed death ligand 1 (PD-L1) is expressed by 20% to 57% of systemic diffuse large B cell lymphomas (DLBCLs). PD-L1 expression in primary cutaneous DLBCL (pcDLBCL) has not been studied so far. Sixteen paraffin-embedded tissue samples of pcDLBCL (13 leg type [LT], 3 others [OT]) were investigated for PD-1, PD-L1, and CD33 expression and the cellular composition of the tumor microenvironment, focusing on myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages. Membrane-bound PD-L1 expression by the tumor cells was observed in all samples, albeit to a variable extent (19.9%). As expected, most DLBCL-LT (10 cases) were classified as activated B cell like type, with a higher PD-L1 score (21.9%) compared with that of the germinal center B cell like type (7.7%). The surrounding infiltrate consisted predominately of CD163(+) M2 rather than CD68(+) macrophages (CD68:CD163=1:4 to 6). Moreover, a considerable proportion of CD33(+) MDSCs with PD-L1 coexpression was admixed. Tumor cells expressed CD33 to variable degrees (2% to 60%). The number of MDSCs or M2 macrophages did not correlate with pcDLBCL subtypes LT or OT. T cells were only a minor component of the tumor microenvironment. We propose that PD-L1(+) tumor cells and PD-L1(+) MDSCs shield the tumor against PD-1(+) tumor-infiltrating lymphocytes, consequently leading to inhibition and diminution of tumor-infiltrating lymphocytes. Moreover, we found a polarization to M2 macrophages, which may contribute to the poor prognosis of DLBCL patients. Thus, targeting of tumor cells and MDSCs using anti-PD-1/anti-PD-L1 or anti-CD33 antibodies might be a worthwhile new approach to treat this aggressive form of cutaneous B-cell lymphoma. © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

CD274 protein
human
CD33 antigen
CD33 protein
human
PDCD1 protein
human
programmed death 1 ligand 1
programmed death 1 receptor
tumor marker
adult
aged
case control study
diffuse large B cell lymphoma
female
human
male
metabolism
middle aged
pathology
retrospective study
skin tumor
tumor microenvironment
very elderly
Adult
Aged
Aged
80 and over
Antigens
CD274
Biomarkers
Tumor
Case-Control Studies
Female
Humans
Lymphoma
Large B-Cell
Diffuse
Male
Middle Aged
Programmed Cell Death 1 Receptor
Retrospective Studies
Sialic Acid Binding Ig-like Lectin 3
Skin Neoplasms
Tumor Microenvironment

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy